Rua Bioscience, PharmAla Sign MDMA Supply Deal for New Zealand

Rua Bioscience and Canadian company PharmAla Biotech have entered into a distribution agreement to supply medicinal MDMA in New Zealand, marking a step toward regulated psychedelic-assisted therapy in the country. Under the deal, Rua Bioscience will import PharmAla's LaNeo™ brand MDMA, which is manufactured to Good Manufacturing Practice (GMP) standards.

The arrangement is designed to serve prescribers who have received authorization from Medsafe, New Zealand's medicines regulatory authority, to administer MDMA as part of treatment for post-traumatic stress disorder. New Zealand has moved to allow MDMA-assisted therapy under a controlled approval pathway, positioning the country among a small group of jurisdictions exploring regulated clinical use of the substance.

Read more SBA Deputy Administrator Visits Citizens Bank of Edmond →

PharmAla Biotech has established itself as a specialized supplier of pharmaceutical-grade MDMA and other psychedelic compounds, with GMP certification central to its commercial strategy. The partnership with Rua Bioscience, which has existing operations and regulatory relationships in New Zealand, provides PharmAla with a regional distribution channel to reach compliant clinical settings.

The agreement reflects growing institutional interest in psychedelic compounds for mental health treatment, particularly for PTSD, a condition with limited therapeutic options. Demand for regulated supply chains is expected to grow as more jurisdictions formalize approval frameworks for such therapies, though the market remains nascent and tightly controlled by national health regulators.

Continue reading at GlobeNewswire - Industry News on Financial Services.